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Abstract
Objective To investigate whether height is associated
with peripheral arterial disease (PAD) in patients with type
2 diabetes.
Research design and methods This was an observational
study performed in 4,528 Chinese patients with type 2
diabetes. Anthropometric measures and the ankle-brachial
index (ABI) were performed on each subject. PAD was
defined as those patients with a history of revascularization
or amputation due to ischemia, or an ABI \0.9.
Results A total of 23.3 % of T2DM patients had PAD
(men 22.9 % and women 23.7 %). The mean age and
height were 57.8 ± 12.5 years and 170.5 cm for men, and
60.0 ± 11.7 years and 158.9 cm for women, respectively.
The ABI and frequency of PAD were higher with
decreasing height quartiles. An inverse association was
observed between height- and gender-adjusted risk of
PAD. This relationship remained unchanged following
further adjustment for potential confounders. Subjects in
the shortest stature group had of 1.174 times higher risk of
PAD for men and 1.143 times for women, compared with
those in the tallest stature group. The multivariate adjusted
hazard ratios (95 % CI) of PAD for a 10-cm height
increase were 0.85 (95 % CI 0.78–0.94).
Conclusion A short stature seems to be associated with
higher risk of PAD in Chinese diabetic patients. However,
the cross-sectional nature of the study limits conclusions
regarding the direction or causality. Further longitudinal
study is warranted in this and other ethnic groups.
Keywords Diabetes mellitus  Height  Peripheral arterial
disease
Height attained in adulthood is a phenotypic expression of
genetic load that is influenced by various environmental
and socioeconomic variables in the perinatal period and
during the growth period. However, an inverse association
between height and all-cause mortality was observed from
a cohort study of 386,627 middle-aged South Korean male
civil servants, even after adjustment for socioeconomic
position and major behavioral risk factors [1]. Several
prospective studies have demonstrated that height is
inversely associated with incidence of or mortality from
cardiovascular disease (CAD) and cerebrovascular disease
(CVD) [2, 3]. Inverse linear associations were observed
between height and coronary heart disease (CHD), stroke,
CVD, injury and total mortality among a total of 510,800
participants with 21,623 deaths [4]. Even after correcting
for conventional cardiovascular risk factors, taller indi-
viduals have more favorable central hemodynamics and
reduced evidence of coronary artery disease compared with
shorter individuals [5].
As an indicator of multifocal atherosclerosis, peripheral
arterial disease (PAD) is emerging as an important aid in
risk stratification of patients with CAD or CVD. Studies
have observed that lower-extremity amputations are much
less common among Taiwanese people of shorter stature
than among white people who are much taller. Similarly,
low procedure rates have been found in other Asian pop-
ulations [6]. The reason for the difference in rates between
ethnic groups in unknown, but height may be a factor. A
strong and statistically significant association was revealed
between height and risk of lower-extremity amputation
among diabetic patients [7].
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PAD is characterized by narrowing or occlusion of the
arteries resulting in gradual reduction of blood supply to
the limbs. Among diabetic patients, PAD is common which
causes suffering and high costs by ulcerations and chronic
pain as well as a major risk factor for need of limb
amputations. However, it remains unknown whether height
affects PAD in type 2 diabetic patients (T2DM). In this
context, our aim was to study the relationship between
height and PAD in T2DM.
Methods
Subjects and methods
Our cross-sectional study included 4,528 T2DM patients
with a diagnosis of diabetes according to American Diabetes
Association criteria (2005). From March 2011 to October
2013, we consecutively recruited patients who were visiting
the Central Hospital of Wuhan for treatment of diabetes. All
participants signed consent forms, and the ethics committee
of the Central Hospital of Wuhan approved the study.
Height, weight, waist circumference (WC) and hip cir-
cumference (HC) were measured for all subjects while they
were wearing light clothing and not wearing shoes. Height
and WC were measured to the nearest 1 mm using a sta-
diometer and a metal anthropometric tape, respectively.
BMI was calculated as weight divided by the square of
height in meters. WC was measured at the level of the
umbilicus and HC at the widest girth of the hip. Waist–hip
ratios (WHpR) were calculated as WC divided by HC.
Systolic blood pressure (SBP) and diastolic blood pres-
sure (DBP) were measured using a standard mercury
sphygmomanometer. After 10 min of rest in the seated
position, two readings were taken on the right arm with
5 min between each recording. The mean of the two values
was used for analysis. Hypertension was defined as an SBP
of 140 mmHg or higher or a DBP of 90 mm Hg or higher or
current use of antihypertensive treatment. Participants were
defined as current cigarette smokers if they reported smok-
ing at least one cigarette per day over the previous year.
Fasting plasma glucose, HDL cholesterol, LDL choles-
terol, triglycerides and total cholesterol were measured
after an overnight fast. Dyslipidemia was defined according
to Third Report of the Expert Panel on Detection, Evalu-
ation, and Treatment of High Blood Cholesterol in Adults
criteria or current treatment with statins. HbA1c was
determined by high-performance liquid chromatography.
Urine albumin and creatinine in the morning urine sample
were analyzed with a biochemical autoanalyzer. Albu-
minuria was determined by the urinary albumin–creatinine
ratio (UACR). Estimated glomerular filtration rate (eGFR)
was calculated on the basis of serum creatinine level, with
the expression of the Modification of Diet in Renal Disease
Study (MDRD) prediction equation for standardized serum
creatinine [8].
The ankle-brachial index (ABI) was measured with an
automatic device that incorporates a sphygmomanometer
and two-way Doppler with an 8-MHZ probe, strictly fol-
lowing the procedure. Briefly, after resting for 5 min in the
supine decubitus position, systolic BP was measured in
both arms and the highest value was selected for calcula-
tion of the ABI (denominator). The systolic BP of the
posterior tibial artery was then measured in each leg, and
the highest value (whether tibial or pedal) was taken as
reference for calculating the individual ABI of each leg
(numerator). The ABI of both the left and right legs was
recorded. For the definition of PAD the lower of the two
values was taken. Normal values of ABI were considered
between 0.9 and 1.3. PAD was defined as those patients
with a history of revascularization or amputation due to
ischemia, or an ABI \0.9.
Statistical analysis
Continuous variables were reported as mean ± SD, and
categorical factors were reported as percentages. All the
continuous variables were normally distributed with
homogenous variances between groups except for triglyc-
eride, which was log transformed before entering into the
model. The intergroup comparisons were performed using a
one-way ANOVA test followed by a Scheffe post hoc test.
Comparisons of the prevalence of PAD were made by means
of a x2 test. To estimate the odds ratio (OR) of PAD in each
quartile, logistic regression was performed, and the highest
quartile was used as reference category. Multivariate
adjusted OR was presented with 95 % CIs. For comparisons
of ABI, ANOVA and ANCOVA were used. Three models
examining the association of height with PAD and ABI were
used under different adjustment schemes. The first model
adjusted only age. The second model additionally adjusted
for duration of diabetes, smoking status, hypertension,
dyslipidemia, current medication use (antihypertensives,
statins, insulin and oral antidiabetes drugs), systolic blood
pressure, diastolic blood pressure, fasting plasma glucose,
HbA1c, eGFR, albuminuria, triglyceride, total cholesterol,
HDL cholesterol, LDL cholesterol and log-transformed tri-
glyceride. The third model additionally adjusted for BMI
and WHpR. P \ 0.05 was considered to be significant. All
statistical analyses were performed using SPSS statistics.
Result
Baseline characteristics of study participants are present in
Table 1. A total of 23.3 % of T2DM patients had PAD
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(men 22.9 % and women 23.7 %). The mean age and
height were 57.8 ± 12.5 years and 170.5 cm for men, and
60.0 ± 11.7 years and 158.9 cm for women, respectively.
The mean duration of type 2 diabetes was 6.7 ± 6.1 years.
Among all participants, 43.3 and 38.4 % had a history of
hypertension and dyslipidemia, respectively. Taller par-
ticipants were more likely to be young, smoker, low BMI,
low WC, low HC, and to have a short history of diabetes,
hypertension, compared with those with short stature
(Table 2).
In both unadjusted and age-adjusted models, there were
significant linear associations of height with the ABI and
frequency of PAD (Table 3). An inverse association was
observed between height- and gender-adjusted risk of
PAD. These relationships remained unchanged following
further adjustment for age, duration of diabetes, smoking
status, hypertension, dyslipidemia, current medication use
(antihypertensives, statins, insulin and oral antidiabetes
drugs), systolic blood pressure, diastolic blood pressure,
fasting plasma glucose, HbA1c, eGFR, albuminuria, tri-
glyceride, total cholesterol, HDL cholesterol, LDL cho-
lesterol and log-transformed triglyceride. Further
adjustment for BMI, waist circumference, hip circumfer-
ence and waist-to- hip ratio did not change the results
significantly. Subjects in the shortest stature group had
1.174 times higher risk of PAD for men and 1.143 times for
women, compared with those in the tallest stature group.
The multivariate adjusted hazard ratios (95 % CI) of PAD
for a 10-cm height increase were 0.85 (95 % CI 0.78–0.94).
Discussion
This study revealed significantly negative associations
between height and PAD among type 2 diabetic patients.
Shorter participants with diabetes were more likely to
accumulate their risks of PAD in their adulthood, com-
pared to taller participants. In the present study, adjust-
ment for potential risk factors did not attenuate the impact
of height.
Atherosclerosis is a generalized process affecting all
segments of the vascular system. The meta-analysis from
121 prospective cohort studies demonstrated that taller
people have a lower risk of death from coronary disease
and stroke subtypes, and show that adult short stature poses
1.5 times higher risk for coronary heart disease (CHD)
morbidity and mortality than being a tall individual [9].
Some studies suggest a 10-cm increment in height to be
associated with a 12–25 % reduction in risk of CHD and
20–24 % reduction in risk of stroke [10, 11]. In this study
taller persons have more favorable central hemodynamics
which may contribute to the inverse association between
height and cardiovascular mortality. Independent of clas-
sical cardiovascular risk factors, height was found to be
inversely associated with carotid atherosclerosis for over-
weight men [12]. PAD is the third leading cause of ath-
erosclerotic cardiovascular morbidity, following coronary
artery disease and stroke. Peripheral, coronary, and carotid
manifestations of atherosclerosis strongly overlap. In our
study, we found that subjects with T2DM in the shortest
stature group had 1.174 times higher risk of PAD for men
and 1.143 times for women, compared with those in the
tallest stature group. The multivariate adjusted hazard
ratios (95 % CI) of PAD for a 10-cm height increase were
0.85 (95 % CI 0.78–0.94).
Table 1 Clinical characteristics of subjects
Total Men Women
n 4,528 2,397 2,131
Age (years) 59.1 (15.7) 57.8 (12.5) 60.0 (11.7)
Medical history
Diabetes duration (years) 6.7 (6.1) 6.5 (6.0) 7.0 (6.2)
Hypertension 43.3 44.2 42.6
Dyslipidemia 38.4 39.3 37.1
Current and ex-smoker 34 60 4
Current medication use
Antihypertensives 14.3 14.5 13.2
Statins 12.9 12.6 13.4
Insulin 33.9 33.2 35.1
Oral antidiabetes drugs 65.2 64.1 68.1
Measurements
Height (cm) 166.0 (7.8) 170.5 (5.7) 158.9 (5.2)
Body weight (kg) 66.1 (9.3) 70.4 (7.7) 61.2 (8.7)
BMI (kg/m2) 24.3 (5.6) 24.4 (5.2) 24.2 (5.8)
Waist circumference (cm) 82.1 (17.3) 83.7 (16.9) 79.8 (17.7)
Hip circumference (cm) 91.2 (18.7) 90.3 (18.2) 92.7 (19.3)
Waist-to-hip ratio 0.90 (0.11) 0.93 (0.12) 0.87 (0.11)
Systolic blood pressure
(mmHg)
128.9 (18.7) 128.5 (17.7) 130.1 (18.4)
Diastolic blood pressure
(mmHg)
77.7 (10.2) 78.2 (10.3) 77.3 (9.6)
Fasting plasma glucose
(mmol/L)
8.4 (5.4) 8.5 (5.2) 8.2 (5.7)
HbA1c (%) 8.1 (2.2) 8.4 (2.3) 7.8 (2.0)
eGFR (ml/min/1.73 m2) 74.5 (26.1) 75.3 (23.2) 73.6 (25.4)
Albuminuria (mg g-1) 141 (57.4) 146 (52.5) 132 (53.9)
Triglyceride 2.2 (4.1) 2.1 (2.3) 2.1 (2.9)
Total cholesterol 4.6 (1.2) 4.5 (1.1) 4.8 (1.1)
HDL cholesterol 1.1 (0.3) 1.0 (0.2) 1.2 (0.3)
LDL cholesterol 2.6 (0.8) 2.5 (0.8) 2.6 (0.9)
ABI 1.01 (0.17) 1.02 (0.16) 1.00 (0.15)
PAD (%) 23.3 20.9 25.7
Data are means (SE) or number (%)
NS not significant
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Table 2 Anthropometric and metabolic characteristics of diabetic patients stratified by sex and height quartile
Q1 Q2 Q3 Q4 P value
Men
n 591 610 606 590
Height (cm) 164.2 (6.2) 168.9 (0.7) 172.3 (1.5) 178.6 (3.9) \0.05
Age (years) 62.0 (12.0) 57.9 (11.8) 56.5 (12.8) 54.7 (12.5) \0.05
Medical history
Diabetes duration (years) 7.0 (6.3) 6.8 (7.0) 5.9 (5.2) 5.2 (5.2) \0.05
Hypertension 48.9 46.5 43.1 41.6 \0.05
Dyslipidemia 36.7 39.6 40.3 39.8 NS
Current and ex-smoker (%) 51 58 61 70 \0.05
Current medication use
Antihypertensives 14.6 14.9 14.3 14.0 NS
Statins 12.4 12.6 12.3 12.8 NS
Insulin 37.6 36.1 32.6 30.8 \0.05
Oral antidiabetes drugs 61.0 62.8 65.3 67.2 \0.05
Measurements
Body weight (kg) 68.1 (6.3) 69.2 (7.0) 70.7 (6.8) 73.4 (9.3) \0.05
BMI (kg/m2) 25.5 (5.8) 24.2 (6.0) 23.8 (5.7) 23.2 (5.4) \0.05
Waist circumference (cm) 86.7 (17.2) 85.1 (17.0) 83.2 (16.8) 81.6 (16.9) \0.05
Hip circumference (cm) 92.1 (18.2) 91.0 (18.6) 90.0 (18.3) 89.3 (18.6) \0.05
Waist-to-hip ratio 0.94 (0.15) 0.95 (0.16) 0.93 (0.15) 0.92 (0.17) NS
Systolic blood pressure (mmHg) 128.3 (20.2) 129.6 (17.1) 126.5 (17.0) 128.6 (16.1) NS
Diastolic blood pressure (mmHg) 77.5 (11.7) 78.6 (9.8) 77.0 (10.1) 79.5 (9.2) NS
Fasting plasma glucose (mmol/L) 8.4 (5.1) 8.3 (5.3) 8.6 (5.6) 8.5 (5.2) NS
HbA1c (%) 8.5 (2.3) 8.3 (2.1) 8.5 (2.4) 8.4 (2.3) NS
eGFR (ml/min/1.73 m2) 74.9 (22.6) 76.1 (24.3) 75.6 (21.7) 75.4 (22.5) NS
Albuminuria (mg g-1) 151 (48.9) 144 (53.3) 143 (51.9) 147 (50.1) NS
Triglyceride 1.9 (2.0) 1.7 (1.3) 2.1 (2.9) 2.5 (2.8) NS
Total cholesterol 4.5 (1.1) 4.4 (1.0) 4.6 (1.3) 4.5 (1.1) NS
HDL cholesterol 1.0 (0.2) 1.0 (0.3) 1.0 (0.2) 1.0 (0.2) NS
LDL cholesterol 2.5 (0.8) 2.5 (0.8) 2.8 (0.8) 2.4 (0.8) NS
ABI 0.91 (0.01) 0.95 (0.01) 1.01 (0.01) 1.07 (0.01) \0.05
PAD(%) 25.3 22.0 19.3 18.0 \0.05
Women
n 526 546 538 521
Height (cm) 153.1 (4.2) 158.4 (1.3) 161.4 (0.5) 167.9 (5.2) \0.05
Age (years) 65.3 (11.4) 60.6 (11.0) 59.7 (10.8) 54.2 (11.2) \0.05
Medical history
Diabetes duration (years) 8.4 (6.3) 7.4 (7.0) 6.7 (5.7) 5.6 (5.2) \0.05
Hypertension 50.3 46.3 41.2 36.3 \0.05
Dyslipidemia 37.8 36.8 36.6 37.4 NS
Current and ex-smoker (%) 6 3 5 2 \0.05
Current medication use
Antihypertensives 14.6 13.3 12.9 12.8 NS
Statins 13.5 13.5 12.6 13.6 NS
Insulin 38.9 36.7 34.8 32.6 \0.05
Oral antidiabetes drugs 68.3 67.5 67.8 69.3 NS
Measurements
Body weight (kg) 58.7 (8.2) 60.4 (8.4) 61.3 (7.1) 64.3 (9.8) \0.05
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Table 2 continued
Q1 Q2 Q3 Q4 P value
BMI (kg/m2) 25.3 (4.9) 24.3 (5.2) 23.7 (4.8) 23.3 (4.9) \0.05
Waist circumference (cm) 83.5 (18.2) 81.1 (17.6) 79.2 (17.9) 78.3 (18.0) \0.05
Hip circumference (cm) 94.7 (19.3) 93.1 (19.8) 92.4 (19.4) 91.6 (19.6) \0.05
Waist-to-hip ratio 0.88 (0.13) 0.87 (0.12) 0.86 (0.13) 0.85 (0.13) NS
Systolic blood pressure (mmHg) 132.6 (19.7) 131.3 (19.5) 129.9 (16.4) 126.5 (17.2) \0.05
Diastolic blood pressure (mmHg) 77.4 (10.4) 76.9 (9.5) 78.3 (9.0) 77.3 (9.5) NS
Fasting plasma glucose (mmol/L) 7.9 (5.6) 8.3 (5.9) 8.2 (4.1) 8.3 (5.6) NS
eGFR (ml/min/1.73 m2) 73.9 (23.4) 72.3 (27.1) 74.8 (28.1) 73.1 (24.6) NS
Albuminuria (mg g-1) 136 (55.2) 130 (51.6) 131 (54.2) 134 (53.9) NS
HbA1c (%) 7.3 (1.7) 7.8 (2.3) 8.1 (1.9) 8.2 (2.2) NS
Triglyceride 1.7 (1.4) 1.7 (1.1) 2.3 (2.5) 2.7 (4.3) \0.05
Total cholesterol 4.6 (1.2) 4.7 (1.0) 4.9 (1.1) 4.9 (1.2) NS
HDL cholesterol 1.2 (0.3) 1.2 (0.3) 1.2 (0.3) 1.1 (0.3) NS
LDL cholesterol 2.6 (1.0) 2.6 (0.8) 2.6 (0.8) 2.6 (0.9) NS
ABI 0.92 (0.02) 0.96 (0.01) 0.99 (0.03) 1.04 (0.02) \0.05
PAD(%) 33.1 25.4 22.3 20.7 \0.05
Men (cm): quartile1 (Q1) 152–167; quartile2 (Q2) 168–170; quartile3 (Q3) 171–174; quartile1 (Q4) 175–188; women (cm): quartile1 (Q1)
142–156; quartile2 (Q2) 157–160; quartile3 (Q3) 161–162; quartile1 (Q4) 163–178
Table 3 Logistic regression models showing associations of ABI and prevalence of PAD with quartiles of height
Q1 Q2 Q3 Q4 P for trend
Men
ABI (mean ± SE)
Model 1 0.908 ± 0.013 0.951 ± 0.013 1.014 ± 0.013 1.065 ± 0.013 \0.001
Model 2 0.921 ± 0.012 0.954 ± 0.013 1.011 ± 0.013 1.061 ± 0.013 0.002
Model 3 0.925 ± 0.013 0.954 ± 0.013 1.006 ± 0.013 1.021 ± 0.013 0.015
Model 4 0.933 ± 0.013 0.957 ± 0.013 0.988 ± 0.013 1.010 ± 0.013 0.041
PAD
Model 1 25.3 22.0 19.3 18.0 \0.001
Model 2 1.221 (1.062–1.337) 1.213 (1.003–1.662) 1.192 (0.863–1.779) 1.000 0.003
Model 3 1.192 (1.137–1.307) 1.131 (0.947–1.429) 1.119 (0.776–1.687) 1.000 0.021
Model 4 1.174 (1.021–1.352) 1.145 (0.957–1.372) 1.118 (0.795–1.599) 1.000 0.037
Women
ABI (mean ± SE)
Model 1 0.917 ± 0.012 0.956 ± 0.013 0.994 ± 0.013 1.037 ± 0.014 \0.001
Model 2 0.921 ± 0.014 0.950 ± 0.011 0.987 ± 0.014 1.031 ± 0.015 0.001
Model 3 0.926 ± 0.013 0.947 ± 0.013 0.983 ± 0.013 1.022 ± 0.013 0.016
Model 4 0.928 ± 0.013 0.945 ± 0.013 0.971 ± 0.013 1.014 ± 0.013 0.038
PAD
Model 1 33.1 25.4 22.3 20.7 \0.001
Model 2 1.247 (1.075–1.421) 1.212 (1.011–1.879) 1.168 (0.825–2.147) 1.000 0.002
Model 3 1.243 (1.039–1.374) 1.207 (1.006–1.621) 1.116 (0.679–1.906) 1.000 0.014
Model 4 1.143 (1.054–1.569) 1.105 (1.004–1.842) 1.169 (0.762–1.976) 1.000 0.041
Q quartile. Q4 was the highest quartile. Model 1 unadjusted model with height. Model 2 adjusted for age. Model 3 adjusted for age, duration of
diabetes, smoking status, hypertension, dyslipidemia, current medication use (antihypertensives, statins, insulin and oral antidiabetes
drugs),systolic blood pressure, diastolic blood pressure, fasting plasma glucose, HbA1c, eGFR, albuminuria, triglyceride, total cholesterol, HDL
cholesterol, LDL cholesterol and log-transformed triglyceride. Model 4 like model 3 and additionally adjusted for BMI, waist circumference, hip
circumference and waist-to-hip ratio
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The mechanism whereby height exerts negative effects
on PAD in diabetic patients is not clear. While undoubtedly
under a large degree of genetic control, height is influenced
by early life environmental factors, which include nutri-
tion, psychosocial stress, chronic illness and living cir-
cumstances. Height and atherosclerosis risk factors such as
obesity are determined by genetic and early environmental
influences. Malnutrition in childhood could be associated
with short stature and poor health outcome [13, 14]. Pre-
vious studies reported inverse associations between total
protein intake and diastolic blood pressure and between
animal protein intake and systolic blood pressure. Hor-
monal factors relevant to growth, the intrauterine envi-
ronment and childhood nutrition have been suggested as a
potential pathway linking impaired peripheral growth to
the risk of atherosclerosis in adulthood [15, 16].
It has been suggested that height may act as a crude
anthropometric marker of IGF-I exposure in earlier life.
The highest IGF-I levels were seen among tall adults with
good linear growth [17]. IGF-1 levels were reported to be
positively associated with height and inversely with risk of
atherosclerosis [18]. In addition to acute metabolic insulin-
like actions, IGF-I may mediate the development of ath-
erosclerosis directly through its effects on nitric oxide
production, vascular smooth muscle cell migration and
proliferation and monocyte behavior and function [19].
Reduced number of nephrons in kidneys could be a
possible explanation for the association between height and
PAD. Birth weight and height are significantly correlated
and low birth weight is known to be associated with renal
disease in adults. This could be due to reduced nephron
numbers, which might be reflected in lower kidney vol-
umes, at least early in life [20–22]. Persons with reduced
number of nephrons are thought to be susceptible to
developing hypertension, because pressure natriuresis
curves are shifted and an elevation of blood pressure is
required to maintain a balance between normal sodium
intake and excretion [23, 24]. The observation that taller
persons have more favorable central hemodynamics may
contribute to the inverse association between height and
PAD [5].
The main limitation of this study concerns its observa-
tional design, so that no cause and effect relation can be
deduced. Future long-term longitudinal studies will be
needed to elucidate these issues. Furthermore, we did not
have any information on socioeconomic status of the par-
ticipants in this study; we could not adjust for socioeco-
nomic status at baseline. The study has been conducted on
type 2 diabetes patients in China and further studies should
be conducted to determine whether our findings are
applicable to other populations. However, despite these
limitations we were able to recruit a large sample of
patients with type 2 diabetes. All height, weight, waist and
hip circumferences in this large study population were
measured by trained personnel.
In conclusion, height is a risk factor for PAD among
T2DM patients. This effect appears to be independent of
other known risk factors. Although the underlying mech-
anism could not be identified, it may be wise to pay
attention to the early detection of PAD in shorter patients
with T2DM.
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